Activating Mutations in Protein Tyrosine Phosphatase Ptpn11 (Shp2) Enhance Reactive Oxygen Species Production That Contributes to Myeloproliferative Disorder

被引:26
|
作者
Xu, Dan [1 ]
Zheng, Hong [1 ]
Yu, Wen-Mei [1 ]
Qu, Cheng-Kui [1 ]
机构
[1] Case Western Reserve Univ, Dept Med, Ctr Stem Cell & Regenerat Med, Div Hematol & Oncol,Case Comprehens Canc Ctr, Cleveland, OH 44106 USA
来源
PLOS ONE | 2013年 / 8卷 / 05期
基金
美国国家卫生研究院;
关键词
OF-FUNCTION MUTATION; GROWTH-FACTOR RECEPTOR; HEMATOPOIETIC STEM; MOUSE MODEL; LEUKEMIA; BINDING; GENE; MITOCHONDRIA; CHECKPOINT; DISTINCT;
D O I
10.1371/journal.pone.0063152
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Gain of function (GOF) mutations in protein tyrosine phosphatase Ptpn11 have been identified in childhood leukemias, and these mutations are sufficient to drive the development of myeloproliferative disorder and malignant leukemias in mice. However, the molecular mechanisms by which Ptpn11 mutations induce these malignancies are not completely understood. Here we report that Ptpn11 GOF mutations cause cytokine hypersensitivity in hematopoietic cells partly by enhancing the production of reactive oxygen species (ROS). GOF mutations D61G or E76K in Ptpn11 increased ROS levels in myeloid progenitors but not in hematopoietic stem cells. Increased ROS enhanced cellular responses to cytokines by promoting cytokine signaling. Treatment with an antioxidant partially corrected cytokine hypersensitivity in Ptpn11 mutant progenitors. Further analyses demonstrated that Ptpn11 mutations increased mitochondrial aerobic metabolism by interacting with a novel substrate in the mitochondria. This study provides new insights into the pathogenic effects of GOF mutations of Ptpn11 and implies that antioxidants may have a therapeutic benefit for the leukemic patients with these mutations.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
    Dietrich A. Ruess
    Guus J. Heynen
    Katrin J. Ciecielski
    Jiaoyu Ai
    Alexandra Berninger
    Derya Kabacaoglu
    Kivanc Görgülü
    Zahra Dantes
    Sonja M. Wörmann
    Kalliope N. Diakopoulos
    Angeliki F. Karpathaki
    Marlena Kowalska
    Ezgi Kaya-Aksoy
    Liang Song
    Eveline A. Zeeuw van der Laan
    María P. López-Alberca
    Marc Nazaré
    Maximilian Reichert
    Dieter Saur
    Mert M. Erkan
    Ulrich T. Hopt
    Bruno Sainz
    Walter Birchmeier
    Roland M. Schmid
    Marina Lesina
    Hana Algül
    Nature Medicine, 2018, 24 : 954 - 960
  • [22] Activating Shp2 mutations cause progressive myeloproliferative disorder in mice.
    Golam Mohi, M.
    Chan, Gordon
    Araki, Toshiyuki
    Yang, Wentien
    Pao, Lily
    Kalaitzidis, Demetrios
    Neel, Benjamin G.
    BLOOD, 2006, 108 (11) : 1032A - 1032A
  • [23] The first Noonan syndrome gene:: PTPN11, which encodes the protein tyrosine phosphatase SHP-2
    Allanson, J
    PEDIATRIC RESEARCH, 2002, 52 (04) : 471 - 471
  • [24] The First Noonan Syndrome Gene: PTPN11, Which Encodes the Protein Tyrosine Phosphatase SHP-2
    Judith Allanson
    Pediatric Research, 2002, 52 (4) : 471 - 471
  • [25] The tyrosine phosphatase Shp2 (PTPN11) directs Neuregulin-1/ErbB signaling throughout Schwann cell development
    Grossmann, Katja S.
    Wende, Hagen
    Paul, Florian E.
    Cheret, Cyril
    Garratt, Alistair N.
    Zurborg, Sandra
    Feinberg, Konstantin
    Besser, Daniel
    Schulz, Herbert
    Peles, Elior
    Selbach, Matthias
    Birchmeier, Walter
    Birchmeier, Carmen
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (39) : 16704 - 16709
  • [26] Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome (vol 29, pg 465, 2001)
    Tartaglia, M
    Mehler, EL
    Goldberg, R
    Zampino, G
    Brunner, HG
    Kremer, H
    van der Burgt, I
    Crosby, AH
    Ion, A
    Jeffery, S
    Kalidas, K
    Patton, MA
    Kucherlapati, RS
    Gelb, BD
    NATURE GENETICS, 2002, 30 (01) : 123 - 123
  • [27] Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations
    Mohi, MG
    Williams, IR
    Dearolf, CR
    Chan, G
    Kutok, JL
    Cohen, S
    Morgan, K
    Boulton, C
    Shigematsu, H
    Keilhack, H
    Akashi, K
    Gilliland, DG
    Neel, BG
    CANCER CELL, 2005, 7 (02) : 179 - 191
  • [28] Protein tyrosine phosphatase non receptor 11 (PTPN11/Shp2) as a driver oncogene and a novel therapeutic target in non-small cell lung cancer (NSCLC).
    Elamin, Yasir
    Toomey, Sinead
    Carr, Aoife
    Gately, Kathy
    Rafee, Shereen
    Grogan, William
    Morris, Patrick G.
    Breathnach, Oscar S.
    Crown, John
    O'Byrne, Kenneth
    Hennessy, Bryan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Protein Tyrosine Phosphatase Non Receptor 11 PTPN11/Shp2 as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer NSCLC
    Elamin, Yasir
    Toomey, Sinead
    Carr, Aoife
    Gately, Kathy
    Rafee, Shereen
    Morris, Patrick
    Crown, John
    Breathnach, Oscar
    O'Byrne, Kenneth J.
    Hennessy, Bryan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S246 - S246
  • [30] Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia
    Bentires-Alj, M
    Paez, JG
    David, FS
    Keilhack, H
    Halmos, B
    Naoki, K
    Maris, JM
    Richardson, A
    Bardelli, A
    Sugarbaker, DJ
    Richards, WG
    Du, JY
    Girard, L
    Minna, JD
    Loh, ML
    Fisher, DE
    Velculescu, VE
    Vogelstein, B
    Meyerson, M
    Sellers, WR
    Neel, BG
    CANCER RESEARCH, 2004, 64 (24) : 8816 - 8820